Skip to main content
Premium Trial:

Request an Annual Quote

Rarecells: Neil Gunn

Rarecells has appointed Neil Gunn as an independent board director. Gunn has management experience in both large and small company settings, including within the liquid biopsy and broader genomics markets. He was previously CEO of IDbyDNA, a metagenomics company recently acquired by Illumina. Prior to that he worked in various roles at Roche.